Pain Management Drugs And Devices Market By Product Type (Electrical Stimulation, Radiofrequency Ablation, Analgesic Infusion Pumps, Neurostimulation), By Drug Class (NSAIDS, Anesthetics, Anticonvulsants, Snti-Migraine Agents, Antidepressents, Opioids, Non-Narcotic Analgesics), By Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Post-Operative Pain, Migraine, Fibromyalgia), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Jun 17, 2016

Key Findings


The global pain management drugs and devices marketwas estimated to grow around $37.8 billion in 2015 and it is forecasted to reach around $50.76 billion at a CAGR of 4.3% during 2015-2022. The major factor driving theglobal pain management drugs and devices market is rising number of chronic pain disorders in all over the world like cancer, migraine etc. along with rising geriatric population which will be boosting the growth of the pain management drugs and devices market in next decade.Usageof pain management devices is rising in all over the world due to growing technological advancements in medicalfield as well as rising medical tourism is expected to drive this market.The rising adoption of new technologiesand medicines helps in minimizing the long stay of patients in the hospitals, huge investment by various economies, rising healthcare industry and favorable government initiatives are also boosting the pain management drugs and devices market.As far as region is concerned, in Asia Pacific the market is expected to grow at a higher rate during2015-2022 with a rising healthcare expenditures in developing countries like India, China etc. Although there are many factors which drives the market and still there are various challenges which are faced by the pain management drugs and devices market such as stringent rules&regulations and lack of novel therapeutics for pain management which adversely affects the market.


Market Segment Insight


The global pain management drugs and device market is segmented on the basis of product type, drug class and by indication. The pain management drugs and devices market is majorly segmented on the basis of products types such as electrical stimulation devices (Transcutaneous Electrical Nerve Stimulation (TENS) devices, neuromuscular electrical stimulation (NMES/EMS) devices, other electrical stimulation devices {Electrotherapy Devices, Combination Devices, TNS, and TMS}), radiofrequency ablation devices,and analgesic infusion pumps (Intrathecalinfusion pumps, external infusion pumps), Neuro-stimulation devices (spinal cord stimulation (scs) devices, deep brain stimulation devices, vagus nerve stimulation devices, sacral nerve stimulation devices) and others.Among all product types, neurostimulationdevice segment holds the largest market share in 2014. The major reason behind the success of this segment in 2014 israising number of DBS & SCS devices implantation in patients suffering from severe pain which generally includes chronic back pain etc. On the basis of drug class the market is further segmented on (Nsaids, anesthetics, anticonvulsants, anti migraine agents, antidepressant, opioids, non-narcotic analgesics)and others. Among all drug class, in 2015 opioids segment holds largest market share which accounted for more than 49% of the total market. The major reason behind the success of this segment is increasing rate of patients suffering from severe pain. On the basis of indication the market is further segmented into arthritic pain, neuropathic pain, cancer pain’, chronic back pain, post-operative pain, migraine, fibromyalgia etc. Among all indication, the neuropathic pain dominates the application areas of different kind of pain management devices. And it is forecasted to grow further at a CAGR of 6% during the forecasted period of time.


Regional Insight


Based on type this market is segmented into North America, Europe, APAC and Row. North America holds thelargest market share and it is the fastest growing region followed byAsia Pacific, Europe and Row.The major reason for the growth of themarket in this region is rising number of patients suffering from severe pains and increasing huge investment in hospitals infrastructure.Another reason for the growth of this pain management drugs and devices market is increasing investments by companies for exploring new technologies to improve patient base in all over the world. The Asia Pacific region is the fastest growing region for the pain management drugs and devices market due to rising aging population and escalating healthcare industry. Key players are also focusing on pain management drugs and devices market due to favorable government initiatives as well as investments by various economiesfor getting better response in future. The overall reach of healthcare sector in India can be raised by offering healthcare solutions to the end consumer.


Competitive Insights


Some of the major market playersAstraZeneca PLC, Baxter International Inc., Boston Scientific Corporation, Eli Lilly, Endo Health Solutions, Halyard Inc., Forest Laboratories, Johnson & Johnson, Medtronic plc., Pfizer Inc., Purdue Pharmaand so on. Acquisitions, expansions and mergers are the key strategies adopted by the market players to sustain in the market.On 27th March 2015, Johnson & Johnson has announced its collaboration with Google for the purpose of advance surgical robots. This collaboration helps in benefiting patients, surgeons and healthcare systems.

CHAP 1. METHODOLOGY & SCOPE 15
1.1. RESEARCH METHODOLOGY 15
1.2. RESEARCH SCOPE & ASSUMPTIONS 15
1.3. LIST OF DATA SOURCES 15


CHAP 2. EXECUTIVE SUMMARY 16
2.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET SUMMARY & KEY BUYING CRITERIA 16
2.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET OUTLOOK 16
2.3. MARKET SEGMENTATION ANALYSIS 16
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 16
2.5. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET VALUE CHAIN ANALYSIS 16
2.6. VENDOR LANDSCAPE 16


CHAP 3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET 17
3.1. MARKET DRIVER ANALYSIS 17
3.1.1. GROWING AGING POPULATION 17
3.1.2. FAVORABLE GOVERNMENT SUPPORT 17
3.1.3. INCREASING PREVALANCE RATE OF CHRONIC PAIN DISORDERS 17
3.2. MARKET RESTRAINT ANALYSIS 17
3.2.1. HIGH COMPETITION AMONG KEY PLAYERS 17
3.2.2. DEARTH OF EXPERIENCED AND SKILLED PERSONNEL 17
3.3. KEY OPPORTUNITIES 17
3.3.1. RISING TECHNOLOGICAL ADVANCEMENTS 17
3.3.2. INCREASING HEALTHCARE INDUSTRY 17
3.4. CHALLENGES 17
3.4.1. STRINGENT REGULATORY GUIDELINES 17
3.4.2. LACK OF NOVEL THERAPEUTICS FOR PAIN MANAGEMENT 17


CHAP 4. INDUSTRY ANALYSIS 18
4.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET– PORTER’S FIVE FORCE MODEL 18
4.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET– PESTEL ANALYSIS 18
4.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET– GAP ANALYSIS 18


CHAP 5. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY PRODUCT TYPE 2012-2022 ($ BILLION) 19
5.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ELECTRICAL STIMULATION DEVICES 2012-2022 ($ BILLION) 19
5.1.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES 2012-2022 ($ BILLION) 19
5.1.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROMUSCULAR ELECTRICAL STIMULATION (NMES/EMS) DEVICES 2012-2022 ($ BILLION) 19
5.1.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY OTHER ELECTRICAL STIMULATION DEVICES 2012-2022 ($ BILLION) 19
5.1.3.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ELECTROTHERAPY DEVICES 2012-2022 ($ BILLION) 19
5.1.3.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY COMBINATION DEVICES 2012-2022 ($ BILLION) 19
5.1.3.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TNS 2012-2022 ($ BILLION) 19
5.1.3.4. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TMS 2012-2022 ($ BILLION) 19
5.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY RADIOFREQUENCY ABLATION DEVICES 2012-2022 ($ BILLION) 19
5.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANALGESIC INFUSION PUMPS 2012-2022 ($ BILLION) 19
5.3.1.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY INTRATHECAL INFUSION PUMPS 2012-2022 ($ BILLION) 19
5.3.1.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY EXTERNAL INFUSION PUMPS 2012-2022 ($ BILLION) 19
5.4. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROSTIMULATION DEVICES 2012-2022 ($ BILLION) 20
5.4.1.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SPINAL CORD STIMULATION (SCS) DEVICES 2012-2022 ($ BILLION) 20
5.4.1.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY DEEP BRAIN STIMULATION DEVICES 2012-2022 ($ BILLION) 20
5.4.1.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY VAGUS NERVE STIMULATION DEVICES 2012-2022 ($ BILLION) 20
5.4.1.4. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SACRAL NERVE STIMULATION DEVICES 2012-2022 ($ BILLION) 20


CHAP 6. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY DRUG CLASS 2012-2022 ($ BILLION) 21
6.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NSAIDS 2012-2022 ($ BILLION) 21
6.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANESTHETICS 2012-2022 ($ BILLION) 21
6.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANTICONVULSANTS 2012-2022 ($ BILLION) 21
6.4. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SNTI-MIGRAINE AGENTS 2012-2022 ($ BILLION) 21
6.5. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANTIDEPRESSENTS 2012-2022 ($ BILLION) 21
6.6. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY OPIOIDS 2012-2022 ($ BILLION) 21
6.7. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NON-NARCOTIC ANALGESICS 2012-2022 ($ BILLION) 21


CHAP 7. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY INDICATION 2012-2022 ($ BILLION) 22
7.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ARTHRITIC PAIN 2012-2022 ($ BILLION) 22
7.2. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROPATHIC PAIN 2012-2022 ($ BILLION) 22
7.3. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY CANCER PAIN 2012-2022 ($ BILLION) 22
7.4. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY CHRONIC BACK PAIN 2012-2022 ($ BILLION) 22
7.5. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY POST-OPERATIVE PAIN 2012-2022 ($ BILLION) 22
7.6. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY MIGRAINE 2012-2022 ($ BILLION) 22
7.7. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY FIBROMYALGIA 2012-2022 ($ BILLION) 22


CHAP 8. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 23
8.1. GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY REGION 2012-2022 ($ BILLION) 23
8.2. NORTH AMERICA 23
8.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 23
8.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.2.3.1. U.S. 23
8.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.2.3.2. CANADA 23
8.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.2.3.3. MEXICO 23
8.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.3. EUROPE 24
8.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 24
8.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.3.3.1. GERMANY 24
8.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.3.3.2. UK 24
8.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.3.3.3. FRANCE 24
8.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.3.3.4. ITALY 24
8.3.3.4.1. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.3.3.4.2. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.3.3.5. SPAIN 24
8.3.3.5.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
8.3.3.5.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
8.3.3.6. REST OF EUROPE 25
8.3.3.6.1. OTHERS MARKET ESTIMATES AND FORECAST2012-2022($ BILLION) 25
8.3.3.6.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 25
8.4. ASIA PACIFIC 25
8.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
8.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 25
8.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
8.4.3.1. CHINA 25
8.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
8.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
8.4.3.2. INDIA 25
8.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 25
8.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 25
8.4.3.3. JAPAN 25
8.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
8.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
8.4.3.4. AUSTRALIA 26
8.4.3.4.1. AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
8.4.3.4.2. AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
8.4.3.5. NEW ZEALAND 26
8.4.3.5.1. NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
8.4.3.5.2. NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
8.4.3.6. OTHERS 26
8.4.3.6.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($ BILLION) 26
8.4.3.6.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($ BILLION) 26
8.5. REST OF THE WORLD 26
8.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
8.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26
8.5.3. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 26
8.5.4. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 26


CHAP 9. COMPETITIVE LANDSCAPE 27
9.1. ASTRAZENECA PLC 28
9.1.1. COMPANY OVERVIEW 28
9.1.2. SCOT ANALYSIS 28
9.1.3. PRODUCT BENCHMARKING 28
9.1.4. STRATEGIC INITIATIVES 28
9.2. BAXTER INTERNATIONAL INC. 28
9.2.1. COMPANY OVERVIEW 28
9.2.2. SCOT ANALYSIS 28
9.2.3. PRODUCT BENCHMARKING 28
9.2.4. STRATEGIC INITIATIVES 28
9.3. BOSTON SCIENTIFIC CORPORATION 28
9.3.1. COMPANY OVERVIEW 28
9.3.2. SCOT ANALYSIS 28
9.3.3. PRODUCT BENCHMARKING 28
9.3.4. STRATEGIC INITIATIVES 28
9.4. ELI LILLY 28
9.4.1. COMPANY OVERVIEW 28
9.4.2. SCOT ANALYSIS 28
9.4.3. PRODUCT BENCHMARKING 28
9.4.4. STRATEGIC INITIATIVES 28
9.5. ENDO HEALTH SOLUTIONS 28
9.5.1. COMPANY OVERVIEW 28
9.5.2. SCOT ANALYSIS 28
9.5.3. PRODUCT BENCHMARKING 28
9.5.4. STRATEGIC INITIATIVES 28
9.6. FOREST LABORATORIES 28
9.6.1. COMPANY OVERVIEW 28
9.6.2. SCOT ANALYSIS 29
9.6.3. PRODUCT BENCHMARKING 29
9.6.4. STRATEGIC INITIATIVES 29
9.7. HALYARD HEALTH 29
9.7.1. COMPANY OVERVIEW 29
9.7.2. SCOT ANALYSIS 29
9.7.3. PRODUCT BENCHMARKING 29
9.7.4. STRATEGIC INITIATIVES 29
9.8. JOHNSON & JOHNSON 29
9.8.1. COMPANY OVERVIEW 29
9.8.2. SCOT ANALYSIS 29
9.8.3. PRODUCT BENCHMARKING 29
9.8.4. STRATEGIC INITIATIVES 29
9.9. MEDTRONIC 29
9.9.1. COMPANY OVERVIEW 29
9.9.2. SCOT ANALYSIS 29
9.9.3. PRODUCT BENCHMARKING 29
9.9.4. STRATEGIC INITIATIVES 29
9.10. PFIZER INC 29
9.10.1. COMPANY OVERVIEW 29
9.10.2. SCOT ANALYSIS 29
9.10.3. PRODUCT BENCHMARKING 29
9.10.4. STRATEGIC INITIATIVES 29
9.11. PURDUE PHARMA 29
9.11.1. COMPANY OVERVIEW 29
9.11.2. SCOT ANALYSIS 29
9.11.3. PRODUCT BENCHMARKING 29
9.11.4. STRATEGIC INITIATIVES 29
9.12. SMITHS MEDICAL 30
9.12.1. COMPANY OVERVIEW 30
9.12.2. SCOT ANALYSIS 30
9.12.3. PRODUCT BENCHMARKING 30
9.12.4. STRATEGIC INITIATIVES 30
9.13. ST. JUDE MEDICAL 30
9.13.1. COMPANY OVERVIEW 30
9.13.2. SCOT ANALYSIS 30
9.13.3. PRODUCT BENCHMARKING 30
9.13.4. STRATEGIC INITIATIVES 30
9.14. STRYKER CORPORATION 30
9.14.1. COMPANY OVERVIEW 30
9.14.2. SCOT ANALYSIS 30
9.14.3. PRODUCT BENCHMARKING 30
9.14.4. STRATEGIC INITIATIVE 30
9.15. TEVA PHARMACEUTICALS (CEPHALON INC.) 30
9.15.1. COMPANY OVERVIEW 30
9.15.2. SCOT ANALYSIS 30
9.15.3. PRODUCT BENCHMARKING 30
9.15.4. STRATEGIC INITIATIVES 30

TABLE 1 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY PRODUCT TYPE 2012-2022 ($ BILLION) 30
TABLE 2 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ELECTRICAL STIMULATION DEVICES 2012-2022 ($ BILLION) 30
TABLE 3 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) DEVICES 2012-2022 ($ BILLION) 31
TABLE 4 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROMUSCULAR ELECTRICAL STIMULATION (NMES/EMS) DEVICES 2012-2022 ($ BILLION) 31
TABLE 5 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY OTHER ELECTRICAL STIMULATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 6 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ELECTROTHERAPY DEVICES 2012-2022 ($ BILLION) 31
TABLE 7 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY COMBINATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 8 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TNS 2012-2022 ($ BILLION) 31
TABLE 9 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY TMS 2012-2022 ($ BILLION) 31
TABLE 10 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY RADIOFREQUENCY ABLATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 11 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANALGESIC INFUSION PUMPS 2012-2022 ($ BILLION) 31
TABLE 12 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY INTRATHECAL INFUSION PUMPS 2012-2022 ($ BILLION) 31
TABLE 13 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY EXTERNAL INFUSION PUMPS 2012-2022 ($ BILLION) 31
TABLE 14 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROSTIMULATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 15 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SPINAL CORD STIMULATION (SCS) DEVICES 2012-2022 ($ BILLION) 31
TABLE 16 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY DEEP BRAIN STIMULATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 17 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY VAGUS NERVE STIMULATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 18 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SACRAL NERVE STIMULATION DEVICES 2012-2022 ($ BILLION) 31
TABLE 19 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY DRUG CLASSS 2012-2022 ($ BILLION) 32
TABLE 20 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NSAIDS 2012-2022 ($ BILLION) 32
TABLE 21 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANESTHETICS 2012-2022 ($ BILLION) 32
TABLE 22 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANTICONVULSANTS 2012-2022 ($ BILLION) 32
TABLE 23 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY SNTI-MIGRAINE AGENTS 2012-2022 ($ BILLION) 32
TABLE 24 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ANTIDEPRESSENTS 2012-2022 ($ BILLION) 32
TABLE 25 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY OPIOIDS 2012-2022 ($ BILLION) 32
TABLE 26 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NON-NARCOTIC ANALGESICS 2012-2022 ($ BILLION) 32
TABLE 27 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY INDICATION 2012-2022 ($ BILLION) 32
TABLE 28 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY ARTHRITIC PAIN 2012-2022 ($ BILLION) 32
TABLE 29 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY NEUROPATHIC PAIN 2012-2022 ($ BILLION) 32
TABLE 30 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY CANCER PAIN 2012-2022 ($ BILLION) 32
TABLE 31 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY CHRONIC BACK PAIN 2012-2022 ($ BILLION) 32
TABLE 32 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY POST-OPERATIVE PAIN 2012-2022 ($ BILLION) 32
TABLE 33 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY MIGRAINE 2012-2022 ($ BILLION) 32
TABLE 34 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY FIBROMYALGIA 2012-2022 ($ BILLION) 32
TABLE 35 GLOBAL PAIN MANAGEMENT DRUGS AND DEVICES MARKET BY REGION 2012-2022 ($ BILLION) 32
TABLE 36 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 37 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 33
TABLE 38 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 39 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 40 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 41 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 42 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 43 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 44 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 45 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 46 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 33
TABLE 47 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 48 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 49 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 50 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 51 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 33
TABLE 52 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
TABLE 53 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 54 ITALY MARKET ESTIMATES AND FORECAST 2012-2022($ BILLION) 34
TABLE 55 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 56 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 57 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 58 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 59 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 60 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 34
TABLE 61 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 62 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 63 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 64 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 65 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 66 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 67 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 68 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 34
TABLE 69 AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 34
TABLE 70 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 71 NEW ZEALAND MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 72 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022 ($ BILLION) 35
TABLE 73 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 74 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
TABLE 75 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35
TABLE 76 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 35

FIGURE 1 MARKET SHARE BY REGIONS 35
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 35
FIGURE 9 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 10 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 11 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 15 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 16 NEW ZEALAND MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 17 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 18 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36
FIGURE 19 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 36

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)